Effect of sulindac and erlotinib vs placebo: On duodenal neoplasia in familial adenomatous polyposis: A randomized clinical trial

JAMA - Journal of the American Medical Association

Volumn 315, Issue 12, 2016, Pages 1266-1275

  Samadder, N Jewel ^a,b   Neklason, Deborah W ^a,b   Boucher, Kenneth M ^a,b   Byrne, Kathryn R ^b   Kanth, Priyanka ^b   Samowitz, Wade ^a,b   Jones, David ^a,b   Tavtigian, Sean V ^a,b   Done, Michelle W ^a   Berry, Therese ^a   Jasperson, Kory ^a   Pappas, Lisa ^a   Smith, Laurel ^a   Sample, Danielle ^a   Davis, Rian ^a   Topham, Matthew K ^a,b   Lynch, Patrick ^c   Strait, Elena ^d   McKinnon, Wendy ^e   Burt, Randall W ^a,b   Kuwada, Scott K ^f   more..

^a UNIVERSITY OF UTAH   (United States)

^b UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d Penrose Hospital   (United States)

^e UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

^f UNIVERSITY OF HAWAII   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APC PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; PLACEBO; SULINDAC; ANTINEOPLASTIC AGENT;

ABDOMINAL PAIN; ACNE; ADENOMATOUS POLYPOSIS COLI GENE; ADULT; ALOPECIA; ARTICLE; BLURRED VISION; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG SAFETY; DRUG WITHDRAWAL; DRY EYE; DRY SKIN; DUODENUM POLYP; DYSPEPSIA; ELEVATED BLOOD PRESSURE; EYE IRRITATION; EYE PAIN; FAMILIAL COLON POLYPOSIS; FATIGUE; FEMALE; FOLLOW UP; GASTROINTESTINAL HEMORRHAGE; GERMLINE MUTATION; HEADACHE; HUMAN; HYPERTENSION; HYPERTRANSAMINASEMIA; LIMB PAIN; MAJOR CLINICAL STUDY; MALE; NAUSEA; ORAL MUCOSITIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECTUM HEMORRHAGE; TONSILLITIS; UNITED STATES; ADENOMATOUS POLYPOSIS COLI; DUODENAL NEOPLASMS; GENETICS; MIDDLE AGED; PATHOLOGY; TUMOR SUPPRESSOR GENE;

ADENOMATOUS POLYPOSIS COLI; ADULT; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DUODENAL NEOPLASMS; ERLOTINIB HYDROCHLORIDE; FEMALE; GENES, APC; HUMANS; MALE; MIDDLE AGED; SULINDAC;

EID: 84962327352     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2016.2522     Document Type: Article

References (34)

1. Groden J, Thliveris A, Samowitz W, et al. Identification and characterization of the familial adenomatous polyposis coli gene. Cell. 1991;66(3): 589-600.
2. Jasperson KW, Tuohy TM, Neklason DW, Burt RW. Hereditary and familial colon cancer. Gastroenterology. 2010;138(6):2044-2058.
3. Biasco G, Pantaleo MA, Di Febo G, Calabrese C, Brandi G, Bülow S. Risk of duodenal cancer in patients with familial adenomatous polyposis. Gut. 2004;53(10):1547.
4. Conio M, Gostout CJ. Management of duodenal adenomas in 98 patients with familial adenomatous polyposis. Gastrointest Endosc. 2001;53(2):265-266.
5. Giardiello FM, Hamilton SR, Krush AJ, et al. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N Engl J Med. 1993;328(18):1313-1316.
6. Giardiello FM, Yang VW, Hylind LM, et al. Primary chemoprevention of familial adenomatous polyposis with sulindac. N Engl J Med. 2002;346 (14):1054-1059.
7. Debinski HS, Trojan J, Nugent KP, Spigelman AD, Phillips RK. Effect of sulindac on small polyps in familial adenomatous polyposis. Lancet. 1995;345 (8953):855-856.
8. Nugent KP, Farmer KC, Spigelman AD, Williams CB, Phillips RK. Randomized controlled trial of the effect of sulindac on duodenal and rectal polyposis and cell proliferation in patients with familial adenomatous polyposis. Br J Surg. 1993;80(12): 1618-1619.
9. Phillips RK, Wallace MH, Lynch PM, et al; FAP Study Group. A randomised, double blind, placebo controlled study of celecoxib, a selective cyclooxygenase 2 inhibitor, on duodenal polyposis in familial adenomatous polyposis. Gut. 2002;50 (6):857-860.
10. Arber N, Eagle CJ, Spicak J, et al; PreSAP Trial Investigators. Celecoxib for the prevention of colorectal adenomatous polyps. N Engl J Med. 2006;355(9):885-895.
11. Steinbach G, Lynch PM, Phillips RK, et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med. 2000;342(26):1946-1952.
12. Woodcock J. Withdrawal of approval of familial adenomatous polyposis indication for Celebrex. https://federalregister.gov/articles/2012/06/08/2012-13900/pfizer-inc-withdrawal-of-approval-of-familial-adenomatous-polyposis-indication-for-celebrex. Accessed February 29, 2016.
13. Coffey RJ, Hawkey CJ, Damstrup L, et al. Epidermal growth factor receptor activation induces nuclear targeting of cyclooxygenase-2, basolateral release of prostaglandins, and mitogenesis in polarizing colon cancer cells. Proc Natl Acad Sci U S A. 1997;94(2):657-662.
14. Eisinger AL, Nadauld LD, Shelton DN, et al. The adenomatous polyposis coli tumor suppressor gene regulates expression of cyclooxygenase-2 by a mechanism that involves retinoic acid. J Biol Chem. 2006;281(29):20474-20482.
15. Roberts RB, Min L, Washington MK, et al. Importance of epidermal growth factor receptor signaling in establishment of adenomas and maintenance of carcinomas during intestinal tumorigenesis. Proc Natl Acad Sci U S A. 2002;99 (3):1521-1526.
16. Torrance CJ, Jackson PE, Montgomery E, et al. Combinatorial chemoprevention of intestinal neoplasia. Nat Med. 2000;6(9):1024-1028.
17. Marks JL, Broderick S, Zhou Q, et al. Prognostic and therapeutic implications of EGFR and KRAS mutations in resected lung adenocarcinoma. J Thorac Oncol. 2008;3(2):111-116.
18. Pao W, Miller VA, Politi KA, et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med. 2005;2(3):e73.
19. Sos ML, Zander T, Thomas RK, Staratschek-Jox A, Claasen J, Wolf J. Expression of signaling mediators downstream of EGF-receptor predict sensitivity to small molecule inhibitors directed against the EGF-receptor pathway. J Thorac Oncol. 2008;3(2):170-173.
20. Gibbons DC, Sinha A, Phillips RK, Clark SK. Colorectal cancer: no longer the issue in familial adenomatous polyposis? Fam Cancer. 2011;10(1):11-20.
21. Bülow S. Results of national registration of familial adenomatous polyposis. Gut. 2003;52(5): 742-746.
22. Morton DG, Macdonald F, Haydon J, et al. Screening practice for familial adenomatous polyposis: the potential for regional registers. Br J Surg. 1993;80(2):255-258.
23. Bülow S, Björk J, Christensen IJ, et al; DAF Study Group. Duodenal adenomatosis in familial adenomatous polyposis. Gut. 2004;53(3): 381-386.
24. Heiskanen I, Kellokumpu I, Järvinen H. Management of duodenal adenomas in 98 patients with familial adenomatous polyposis. Endoscopy. 1999;31(6):412-416.
25. Lynch TJ, Fenton D, Hirsh V, et al. A randomized phase 2 study of erlotinib alone and in combination with bortezomib in previously treated, advanced non-small cell lung cancer. J Thorac Oncol. 2009;4 (8):1002-1009.
26. Wheatley-Price P, Ding K, Seymour L, Clark GM, Shepherd FA. Erlotinib for advanced non-small cell lung cancer in the elderly: an analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21. J Clin Oncol. 2008;26(14): 2350-2357.
27. Lynch PM, Ayers GD, Hawk E, et al. The safety and efficacy of celecoxib in children with familial adenomatous polyposis. Am J Gastroenterol. 2010; 105(6):1437-1443.
28. Tonelli F, Valanzano R, Messerini L, Ficari F. Long-term treatment with sulindac in familial adenomatous polyposis: is there an actual efficacy in prevention of rectal cancer? J Surg Oncol. 2000; 74(1):15-20.
29. Cruz-Correa M, Hylind LM, Romans KE, Booker SV, Giardiello FM. Long-term treatment with sulindac in familial adenomatous polyposis: a prospective cohort study. Gastroenterology. 2002;122(3):641-645.
30. Niv Y, Fraser GM. Adenocarcinoma in the rectal segment in familial polyposis coli is not prevented by sulindac therapy. Gastroenterology. 1994;107(3): 854-857.
31. Thorson AG, Lynch HT, Smyrk TC. Rectal cancer in FAP patient after sulindac. Lancet. 1994;343 (8890):180.
32. Sulindac [package insert]. Corona, CA: Watson Laboratories; 2008. http://pi.actavis.com/data
33. Qi WX, Sun YJ, Shen Z, Yao Y. Risk of interstitial lung disease associated with EGFR-TKIs in advanced non-small cell lung cancer: a meta-analysis of 24 phase 3 clinical trials. J Chemother. 2015;27(1):40-51.
34. Shi L, Tang J, Tong L, Liu Z. Risk of interstitial lung disease with gefitinib and erlotinib in advanced non-small cell lung cancer: a systematic review and meta-analysis of clinical trials. Lung Cancer. 2014; 83(2):231-239.